Drugs / GSK208141
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00698893 | May → Jul 1992 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00698490 | Aug 1995 → Jan 1997 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00697567 | Sep 1992 → Dec 1997 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT00224484 | Apr 2004 → Jul 2007 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00224471 | Dec 2003 → Sep 2005 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00698568 | Oct 1996 → Apr 1999 | — | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00699764 | Mar 1996 → Oct 1999 | herpes simplex infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK208141 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00699764 ↗ |
| Known as | gD2t | “Herpes Simplex Candidate Vaccine (gD2t)” NCT00698568 ↗1“Herpes Simplex Candidate Vaccine (gD2t)” NCT00699764 ↗ |
| Modality | Vaccine | “candidate vaccine” NCT00224471 ↗ |
| Route | Intramuscular | “3 IM doses” NCT00224471 ↗ |